LESS HOSPITAL.
Learn how you can DO MORE with Corlanor to reduce the risk
of hospitalization for worsening heart failure
®
CorlanorHCP.com
Bradycardia and Conduction Disturbances: Bradycardia,
sinus arrest and heart block have occurred with Corlanor®.
The rate of bradycardia in patients treated with Corlanor®
compared to placebo was 6% (2.7% symptomatic; 3.4%
asymptomatic) vs. 1.3% per patient-year, respectively. Risk
factors for bradycardia include sinus node dysfunction,
conduction defects, ventricular dyssynchrony, and use of
other negative chronotropes. Concurrent use of verapamil
or diltiazem also increases Corlanor® exposure, contributes
to heart rate lowering, and should be avoided. Avoid use of
Corlanor® in patients with 2nd degree atrioventricular block
unless a functioning demand pacemaker is present.
Adverse Reactions: The most common adverse reactions
reported at least 1% more frequently with Corlanor® than
placebo and that occurred in more than 1% of patients
treated with Corlanor® were bradycardia (10% vs. 2.2%),
hypertension or increased blood pressure (8.9% vs. 7.8%),
atrial fibrillation (8.3% vs. 6.6%), and luminous phenomena
(phosphenes) or visual brightness (2.8% vs. 0.5%).
Please see Brief Summary of full Prescribing
Information on following page.
References: 1. Corlanor® (ivabradine) Prescribing Information,
Amgen. 2. Swedberg K, Komajda M, Böhm M, et al. Lancet.
2010;376:875-885.
ARR = absolute risk reduction; BPM = beats per minute; CV = cardiovascular;
HF = heart failure; LVEF = left ventricular ejection fraction.